Iodine in mammary and prostate pathologies

Current Chemical Biology

Volumn 5, Issue 3, 2011, Pages 177-182

  Anguiano, Brenda ^a   Aceves, Carmen ^a  

^a INSTITUTO DE NEUROBIOLOGÍA   (Mexico)

Author keywords

Apoptosis; Cancer; Iodine; Iodolactone; Mammary gland; Prostate

Indexed keywords

IODINE; IODINE DERIVATIVE; IODOLACTONE DERIVATIVE; IODOLIPID DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; THYROID HORMONE; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; APOPTOSIS; ASIAN; BENIGN TUMOR; BREAST CANCER; DIET SUPPLEMENTATION; DIETARY INTAKE; HUMAN; JAPAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

ANIMALIA;

EID: 80051777417     PISSN: None     EISSN: 18723136     Source Type: Journal    
DOI: 10.2174/187231311796765049     Document Type: Review

References (58)

1. Cocchi M, Venturi S. Iodide, antioxidant function and omega-6 and omega-3 fatty acids: a new hypothesis of biochemical cooperation? Prog Nutr 2000; 2: 15-9.
2. Thrall KD, Bull RJ. Differences in the distribution of iodine and iodide in the Sprague-Dawley rat. Fundam Appl Toxicol 1990; 15: 75-81.
3. Thrall KD, Sauer RL, Bull RJ. Evidence for thyroxine formation following iodine administration in Sprague-Dawley rats. J Toxicol Environ Health 1992; 37: 443-9.
4. Eskin BA, Grotkowski CE, Connolly CP, Ghent WR. Different tissue responses for iodine and iodide in rat thyroid and mammary glands. Biol Trace Elem Res 1995; 49: 9-18.
5. Ghent WR, Eskin BA, Low DA, Hill LP. Iodine replacement in fibrocystic disease of the breast. Cancer J Surg 1993; 36: 453-60.
6. Kessler JH. The effect of supraphysiological levels of iodine on patients with cyclic mastalgia. The Breast J 2004; 10: 328-36.
7. Lopez-Otin C, Diamandis EP. Breast and prostate cancer: An analysis of common epidemiological, genetic, and biological features. Endocrinol Rev 1998; 19: 365-96.
8. Spitzweg C, Joba W, Eisenmenger W, Heufelder E. Analysis of human symporter gene expression in extrathyroidal tissues and cloning of its complementary deoxyribonucleic acids from salivary gland, mammary gland and gastric mucosa. J Clin Endocrinol Metab 1998; 83: 1746-51.
9. Dohan O, De la Vieja A, Paroder V, et al. The sodium/iodide symporter (NIS): Characterization, regulation, and medical significance. Endocr Rev 2003; 24: 48-77.
10. Anguiano B, López A, Delgado G, Romero C, Aceves C. Deiodinase type 1 is expressed in prostate of pubescent rats and is modulated by prolactin and sex hormones. J Endocrinol 2006; 190: 1-10.
11. Aceves C, Rodón C, Ramírez-C I, et al. Mammary 5'deiodinase (5'D) during the breeding cycle of the rat: indirect evidence that 5'D type I is specific to the alveolar epithelium. Endocrine 1995; 3: 95-9.
12. th Annual Meeting of the American Thyroid Association. New York, 2007. abs, 114
13. Aceves C, Anguiano B. Is iodine an antioxidant and antiproliferative agent for the mammary and prostate glands? In: Preedy VR, Burrow GN, Watson RR (Eds), Comprehensive Handbook of Iodine. Nutritional, endocrine and pathological aspects. Academic Press 2009, 249-57.
14. Cann SA, van Netten JP, van Netten C. Hypothesis: iodine, selenium and the development of breast cancer. Cancer Causes Control 2000; 11: 121-27.
15. Hou X, Chai C, Quian Q, Yan X, Fan X. Determination of chemical species of iodine in some seaweeds (I). Sci Total Environment. 1997; 204: 215-21.
16. Teas J, Pino S, Critchley A, Braverman LE. Variability of iodine content in common commercially available edible seaweeds. Thyroid 2004; 14: 836-41.
17. Alfaro-Hernández Y, Aceves C. The other face of iodine: a protective free radical? In: Díaz-Muñoz M, Santamaria A Eds. Prooxidant reactions: Physiological and pathological implications. Pandalai 2009; 241-53.
18. Strum JM. Site of iodination in rat mammary gland. Anat Rec 1978; 192: 235-44.
19. Smyth PP. Role of iodine in antioxidant defense in thyroid and breast disease. Biofactors 2003; 19: 121-30.
20. Aceves C, Anguiano B, Delgado G. Is Iodine a gatekeeper of the integrity of the mammary gland? J Mammary Gland Biol Neoplasia 2005; 10: 189-96.
21. Seidman H, Stellman SD, Mushinski MH. A different perspective on breast cancer risk factors: some implications of the nonattributable risk. CA Cancer J Clin 1982; 32: 301-13.
22. Helzlsouer KJ, Couzi R. Hormones and breast cancer. Cancer 1995; 76: 2059-63.
23. Wynne-Edwards K E. Breast cancer etiology and prevention from an evolutionary perspective. In: Review of lifestyle and environmental risk factors for breast cancer. The Canadian Breast Cancer Initiative (CBCI). Workshop on Primary Prevention of Breast Cancer. Volume III, Québec Canada. 2000; 1-31.
24. Shah NM, Eskin BA, Krouse TB, Sparks CE. Iodoprotein formation by rat mammary glands during pregnancy and early postpartum period. Proc Soc Exp 1986; 181: 443-49.
25. Russo J, Russo IH. Role of differentiation in the pathogenesis and prevention of breast cancer. Endo Related Cancer 1997; 4: 7-21.
26. Yang PS, Yang TL, Liu CL, Wu CW, Shen CY. A case control study of breast cancer in Taiwan. A low incidence area. Br J Cancer 1997; 75: 752-6.
27. Newcomb PA, Storer BE, Longnecker MP, et al. Lactation and reduced risk of premenopausal breast cancer. N Engl J Med 1994; 330: 81-7.
28. Michels KB, Willett WC, Rosner BA, et al. Prospective assessment of breastfeeding and breast cancer incidence among 89887 women. Lancet 1996; 347: 431-36.
29. Stoddard FR 2nd, Brooks AD, Eskin BA, Johannes GJ. Iodine alters gene expression in the MCF7 breast cancer cell line: evidence for an anti-estrogen effect of iodine. Int J Med Sci 2008; 5: 189-96.
30. Cofey DS, Walsh PC. Clinical experimental studies of benign prostatic hyperplasia. Urol Clin North Am 1990; 17: 461-75.
31. Giles GG, Severi DR, English DR, et al. Sexual factors and prostate cancer. BJU International 2003; 92: 211-16.
32. 3) in prostate of sexually active rats. The Prostate 2009; 69: 1651-59.
33. 3) depends on sympathetic innervation. Biol Reprod 2011; 84, 118-23.
34. Rao J, Yang J, Liu Z, et al. Hypothetic association between greater sympathetic activity and prostate cancer. Med Hypotheses 2008; 71: 442-43.
35. Rossato SD, Basso GM, John AB, et al. Pulmonary arterial hypertension and thyroid disease. J Bras Pneumol 2009; 35: 179-85.
36. Kato N, Funahashi H, Ando K, Takagi H. Suppressive effect of iodine preparations on proliferation of DMBA-induced breast cancer in rat. J Jpn Soc Cancer Ther 1994; 29: 582-8.
37. Soriano O, Delgado G, Anguiano B, et al. Antineoplastic effect of iodine and iodide in DMBA-induced mammary tumors. Association between lactoperoxidase and estrogen-adduct production. Endocrine Related Cancer 2011; 18: 529-39.
38. Vitale M, Di Matola T, D'Ascoli F, et al. Iodide excess induces apoptosis in thyroid cells through a p53-independent mechanism involving oxidative stress. Endocrinology 2000; 141: 598-605.
39. Zhang L, Sharma S, Zhu LX, et al. Nonradioactive iodide effectively induces apoptosis in genetically modified lung cancer cells. Cancer Res 2003; 63: 5065-72.
40. Boeynaems JM, Hubbard WC. Transformation of arachidonic acid into an iodolactone by the rat thyroid. J Biol Chem 1980; 255: 9001-4.
41. Thomasz L, Oglio R, Dagrosa MA, Krawiec L, Pisarev MA, Juvenal GJ. 6 Iodo-delta-lactone reproduces many but not all the effects of iodide. Mol Cell Endocrinol. 2010; 323: 161-66.
42. Aceves C, García-Solís P, Arroyo-Helguera O, Vega-Riveroll L, Delgado G, Anguiano B. Antineoplastic effect of iodine in mammary cancer. Participation of 6-iodolactone (6-IL) and peroxisome proliferator-activated receptors (PPAR). Molecular Cancer 2009; 8: 33-6.
43. Arroyo-Helguera O, Anguiano B, Delgado G, Aceves C. Uptake and antiproliferative effect of molecular iodine in the MCF-7 breast cancer cell line. Endocrine Related Cancer 2006: 13; 1147-58.
44. Arroyo-Helguera, O.; Rojas, E.; Delgado, G.; Aceves, C. Signaling pathways involved in the antiproliferative effect of molecular iodine in normal and tumoral breast cells: evidence that 6- iodolactone mediates apoptotic effects. Endocr Related Cancer 2008; 15: 1003-11.
45. Tan WC, Privett OS, Goldyne ME. Studies of prostaglandins in rat mammary tumors induced by 7,12-dymethyl-benz(a)anthracene. Cancer Research 1974; 34: 3229-31.
46. Bennett A, Charlier EM, McDonald AM, Simpson JS, Stamford IF, Zebro T. Prostaglandins and breast cancer. Lancet 1977; 2: 624-26.
47. Pham H, Banerjee T, Ziboh VA Suppression of cyclooxygenase-2 overexpression by 15S-hydroxyeicosatrienoic acid in androgendependent prostatic adenocarcinoma cells. Int J Cancer. 2004; 111: 192-97.
48. Howe LR, Subbaramaiah K, Brown AMC, Dannenberg AJ. Cyclooxygenase- 2: a target for the prevention and treatment of breast cancer. Endocrine-Related Cancer 2001; 8: 97-114.
49. Kliewer SA, Forman BM, Blumberg B, et al. Differential expression and activation of a family of murine peroxisome proliferatoractivated receptors. Proc Natl Acad Sci USA 1994; 91:7355-59.
50. Shen Q, Brown PH. Novel agents for the prevention of breast cancer: targeting transcription factors and signal transduction pathways. J Mammary Gland Biol Neoplasia 2003; 8: 45-73.
51. Kliewer SA, Sundseth SS, Jones SA, et al. Fatty acids and eicosanoids regulate gene expression through direct interaction with peroxisome proliferator-activated receptors α and γ. Proc Nat Acad Sci USA 1997; 94: 4318-23.
52. Sigal E. The molecular biology of mammalian arachidonic and metabolism. Am. J. Phys. 1991; 260: L13-L28.
53. Nuñez-Anita RE, Arroyo-Helguera O, Cajero-Juárez M, López-Bojorquez L, Aceves C. A complex between 6-iodolactone and the peroxisome proliferator-activated receptor type gamma may mediate the antineoplastic effect of iodine in mammary cancer. Prostag Other Lipid Mediat 2009; 89: 34-42.
54. Samid D, Wells M, Greene ME, Shen W, Palmer CN, Thibault A. Peroxisome proliferators - activated receptor γ as a novel target in cancer therapy: Binding and activation by aromatic fatty acid with clinical antitumoral activity. Clin Cancer Res 2000; 6: 933-41.
55. Rosner H, Torremante P, Moller W, Gärtner R. Antiproliferative/ cytotoxic activity of molecular iodine and iodolactones in various human carcinoma cell lines. No interfering with EGF-signaling but evidence for apoptosis. Exp Clin Endocrinol Diabetes 2010; 118: 410-19.
56. Elrod HA, Sun SY. PPAR gamma and apoptosis in cancer. PPAR Res 2008, 70: 41-65.
57. Mendieta I, Nuñez-Anita RE, Delgado G, Aceves C. Differential effect of iodine on the implantation and metastatic potential of xenografts from two different human breast cancer cell lines. 101Th Annual Meeting, AACR, Orlando FL. 2011, abs 4224
58. RD SABCS 2010, abs 14